PapersFlow Research Brief
Liver physiology and pathology
Research Guide
What is Liver physiology and pathology?
Liver physiology and pathology encompasses the mechanisms, cellular processes, and therapeutic targets involved in liver fibrosis, including the roles of hepatic stellate cells, TGF-β signaling, macrophages, oxidative stress, angiogenesis, hepatocyte growth factor, and inflammation in disease progression and regeneration.
This field examines liver fibrosis as the excessive accumulation of extracellular matrix proteins like collagen in chronic liver diseases, leading to cirrhosis, liver failure, and portal hypertension. Key cellular players include hepatic stellate cells and macrophages, with pathways such as TGF-β signaling and MET signaling driving fibrogenesis. The topic includes 56,738 works, focusing on liver regeneration and therapeutic interventions.
Topic Hierarchy
Research Sub-Topics
Hepatic Stellate Cell Activation in Fibrosis
This sub-topic studies transdifferentiation of hepatic stellate cells (HSCs) into myofibroblasts driving extracellular matrix deposition. Researchers explore signaling pathways and antifibrotic targets to halt activation.
TGF-β Signaling in Liver Fibrogenesis
Investigates Smad-dependent and independent TGF-β pathways promoting fibrogenic gene expression in hepatocytes and HSCs. Studies evaluate pathway inhibitors and resolution mechanisms in regression.
Macrophage Roles in Liver Fibrosis
Examines pro-fibrogenic M2 macrophages versus resolution-promoting M1/Ly6C-low subsets in inflammation-fibrosis crosstalk. Research focuses on chemokine signaling and therapeutic repolarization strategies.
Liver Regeneration Mechanisms
Covers hepatocyte proliferation, progenitor activation, and matrix remodeling post-injury or partial hepatectomy. Studies identify growth factors like HGF and barriers in fibrotic livers.
Oxidative Stress in Liver Fibrosis
Explores ROS generation by NADPH oxidases and mitochondria activating fibrogenic signaling in stellate cells. Antioxidant interventions and Nrf2 pathway modulation are key research foci.
Why It Matters
Liver physiology and pathology research identifies therapeutic targets for liver fibrosis and hepatocellular carcinoma (HCC), conditions that often necessitate transplantation. Sorafenib extended median survival by nearly 3 months in advanced HCC patients compared to placebo in a phase III trial (Llovet et al., 2008, "Sorafenib in Advanced Hepatocellular Carcinoma"). In the Asia-Pacific region, sorafenib improved overall survival from 4.2 to 6.5 months (Cheng et al., 2008, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma"). Lenvatinib showed non-inferiority to sorafenib in first-line unresectable HCC treatment, with a median survival of 13.6 months versus 12.3 months (Kudo et al., 2018, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma"). These advances inform systemic therapies like regorafenib and lenvatinib for HCC management (Kudo, 2017, "A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib").
Reading Guide
Where to Start
"Liver fibrosis" by Bataller and Brenner (2005) provides a foundational overview of extracellular matrix accumulation, cirrhosis progression, and key cellular mechanisms, making it ideal for initial reading.
Key Papers Explained
Bataller and Brenner (2005, "Liver fibrosis") establishes the core pathology of fibrosis and stellate cell roles, which Llovet et al. (2008, "Sorafenib in Advanced Hepatocellular Carcinoma") builds upon by demonstrating sorafenib's survival benefits in fibrosis-related HCC. Cheng et al. (2008, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma") extends this regionally, while Kudo et al. (2018, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma") compares next-line therapies. Kudo (2017, "A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib") synthesizes these into evolving treatment paradigms.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues to emphasize therapeutic targeting of hepatic stellate cells, TGF-β signaling, and macrophages in fibrosis, with persistent focus on HCC therapies like sorafenib and lenvatinib as seen in top-cited works. No recent preprints or news alter these directions.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Sorafenib in Advanced Hepatocellular Carcinoma | 2008 | New England Journal of... | 12.7K | ✓ |
| 2 | Single Lgr5 stem cells build crypt-villus structures in vitro ... | 2009 | Nature | 6.8K | ✕ |
| 3 | A New Era of Systemic Therapy for Hepatocellular Carcinoma wit... | 2017 | PubMed | 5.9K | ✕ |
| 4 | Efficacy and safety of sorafenib in patients in the Asia-Pacif... | 2008 | The Lancet Oncology | 5.8K | ✕ |
| 5 | Sorafenib in Advanced Hepatocellular Carcinoma | 2008 | — | 5.6K | ✕ |
| 6 | Hepatocellular Carcinoma: Epidemiology and Molecular Carcinoge... | 2007 | Gastroenterology | 5.4K | ✕ |
| 7 | Chapter 4 Preparation of Isolated Rat Liver Cells | 1976 | Methods in cell biology | 5.3K | ✕ |
| 8 | Lenvatinib versus sorafenib in first-line treatment of patient... | 2018 | The Lancet | 5.2K | ✓ |
| 9 | EASL–EORTC Clinical Practice Guidelines: Management of hepatoc... | 2012 | Journal of Hepatology | 5.2K | ✕ |
| 10 | Liver fibrosis | 2005 | Journal of Clinical In... | 4.6K | ✕ |
Frequently Asked Questions
What is liver fibrosis?
Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases (Bataller and Brenner, 2005, "Liver fibrosis"). Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension, often requiring liver transplantation. Hepatic stellate cells play a central role in this process.
How does sorafenib treat advanced hepatocellular carcinoma?
Sorafenib extends median survival and time to radiologic progression by nearly 3 months in patients with advanced hepatocellular carcinoma compared to placebo (Llovet et al., 2008, "Sorafenib in Advanced Hepatocellular Carcinoma"). This was demonstrated in a phase III trial (NCT00105443). Similar benefits were observed in Asia-Pacific patients, with survival increasing from 4.2 to 6.5 months (Cheng et al., 2008).
What role do hepatic stellate cells play in liver pathology?
Hepatic stellate cells are key mediators in liver fibrogenesis, activated by factors like TGF-β signaling to produce extracellular matrix. Their involvement is central to the progression of fibrosis in chronic liver diseases (Bataller and Brenner, 2005, "Liver fibrosis"). Targeting these cells offers potential therapeutic avenues.
What are the outcomes of lenvatinib versus sorafenib in HCC?
Lenvatinib demonstrated non-inferiority to sorafenib in first-line treatment of unresectable hepatocellular carcinoma, achieving a median survival of 13.6 months compared to 12.3 months (Kudo et al., 2018, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma"). This phase 3 trial supports its use in HCC management.
What methods are used to prepare isolated rat liver cells?
Preparation of isolated rat liver cells is a foundational method for studying liver physiology (Seglen, 1976, "Chapter 4 Preparation of Isolated Rat Liver Cells"). This technique enables isolation of hepatocytes and other cell types for research on regeneration and pathology. It has been cited extensively in fibrosis studies.
What is the current state of HCC management guidelines?
EASL–EORTC Clinical Practice Guidelines provide recommendations for managing hepatocellular carcinoma, incorporating therapies like sorafenib (2012, "EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma"). These guidelines address surveillance, diagnosis, and treatment in liver pathology contexts.
Open Research Questions
- ? How can hepatic stellate cell activation be specifically inhibited to halt liver fibrosis progression?
- ? What are the precise roles of macrophages and TGF-β signaling in balancing liver regeneration and fibrogenesis?
- ? How does MET signaling interact with oxidative stress and angiogenesis in chronic liver diseases?
- ? Which combinations of hepatocyte growth factor and anti-inflammatory agents most effectively reverse advanced fibrosis?
- ? What molecular mechanisms underlie inflammation-driven transitions from fibrosis to hepatocellular carcinoma?
Recent Trends
The field maintains steady emphasis on fibrosis mechanisms and HCC treatments, evidenced by 56,738 works with high citations for sorafenib trials (Llovet et al., 2008; Cheng et al., 2008).
Advances include lenvatinib's validation against sorafenib (Kudo et al., 2018) and systemic options like regorafenib (Kudo, 2017).
No new preprints or news in the last 12 months reported.
Research Liver physiology and pathology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Liver physiology and pathology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers